• The document is the written transcript of the Q1 FY27 Earnings Conference Call held on August 17, 2026, at 04:30 PM IST.
  • The purpose of the event was to discuss the company's financial results for the first quarter of FY26-27 and provide a business update.
  • The call was hosted post-results, as the press release and investor presentation had been submitted to the stock exchanges on the previous Friday.
  • Management participants included:
  • Mr. Pranav Choksi – CEO & Whole-Time Director
  • Mr. Devkinandan Roonghta – Chief Financial Officer
  • Mr. Avik Das – Investor Relations Head
  • Ms. Ami Shah – Company Secretary & Compliance Officer
  • The transcript includes a standard safe harbor statement regarding forward-looking statements, advising participants to review relevant disclosures and risk factors.
  • The company did not indicate that any unpublished price sensitive information (UPSI) would be shared during the call.

Financial Highlights Discussed (Q1 FY27 vs. Q1 FY26):

  • Revenue from Operations: INR 260.8 Cr (vs. INR 226.9 Cr)
  • EBITDA: INR 47.2 Cr (vs. INR 33.2 Cr); Margin: 18.09% (vs. 14.6%)
  • Profit Before Tax (PBT): INR 30.1 Cr (vs. INR 16.3 Cr); Margin: 11.56% (vs. 7.1%)
  • Profit After Tax (PAT): INR 22.46 Cr (vs. INR 12.1 Cr); Margin: 8.61% (vs. 5.3%)

Financial Highlights (Q1 FY27 vs. Q4 FY26):

  • Revenue from Operations: INR 260.8 Cr (vs. INR 252.1 Cr)
  • EBITDA: INR 47.2 Cr (vs. INR 44.7 Cr); Margin: 18.09% (vs. 17.74%)
  • Profit Before Tax (PBT): INR 30.1 Cr (vs. INR 27.6 Cr); Margin: 11.56% (vs. 10.96%)
  • Profit After Tax (PAT): INR 22.46 Cr (vs. INR 20.6 Cr)

Operational & Strategic Updates Discussed:

  • Indore Plant: Running to plan; qualification and validations complete. Depot and microsphere suites nearing completion. Lipid-based antifungal capability being added.
  • Critical Care Division: Launched a monobactam and beta-lactamase inhibitor combination post patent expiry.
  • Sparsh Division (Nutritionals): Completed a full quarter on rebuilt channel; focus shifted to own manufactured brands; entered Northeast and J&K markets.
  • Women's Health: Ferticare brand retains leadership; Puregraf group secured entry into major corporate IVF chains.
  • Aesthetics (Botulinum Toxin): Described as the number 2 brand in India (Toxin Type A). In-licensed filler and biostimulator portfolio progressing for launch in FY27.
  • International Business: Model shifting from distributor-led to IP-led. Licensing progressed in Europe; CMO and licensing deal with a North American party; first CMO orders received in Australia. Approvals secured in 8 countries.
  • GLP-1 (Semaglutide): CMO partnership with Hetero; operations began with residual traction in Q1, expected to pick up in Q2 and Q3. The company reiterated it will not front-end the product.
  • Capacity & Revenue: Indore capacity utilization expected to reach 40-45% by year-end. Peak revenue potential from existing facilities (Navsari + Indore) estimated at INR 1,600 - 2,000 Cr, dependent on product mix.
  • Guidance: Management reiterated medium-term expectations and a commitment to a minimum 15-20% year-on-year growth.

Additional Notes Section

  • The transcript was provided as an attachment to the regulatory filing and is marked 'E&OE – Edited for factual errors.'
  • The document is a verbatim record of the earnings call, including the Q&A session with analysts.
  • No new financial data beyond what was published in the results was disclosed in this transcript.